EU Cyber Resilience Act Guide for Pharmaceutical Manufacturing Automation Vendors

Automation products sold to EU pharmaceutical manufacturers — including MES (manufacturing execution systems), batch record management software, SCADA systems for process control, process analytical technology (PAT) platforms, cleanroom environmental monitoring systems, and laboratory information management systems (LIMS) — are products with digital elements subject to the CRA. Classification requires analysis of the product's role in the manufacturing process: systems that directly control critical process parameters — temperature, pressure, mixing ratios — in pharmaceutical manufacturing are strong candidates for Class II Important Products, given the potential public health consequences of process control compromise. MES and batch record systems that maintain GMP records without direct process control may qualify as Class I. Vendors must document their classification analysis and ensure it is consistent with the EU Annex 11 (computerised systems) GMP risk assessment that customers will expect.

Annex I security requirements must be implemented in a manner compatible with GMP computerised systems validation requirements under EU GMP Annex 11. Core security obligations include: implementing role-based access control with individual user accounts — shared accounts are incompatible with both Annex I and GMP audit trail requirements; ensuring all audit trails are tamper-evident and capture who did what and when for all operations affecting batch records or process parameters; encrypting data transmission between field devices, servers, and any cloud components; providing authenticated and logged remote access for vendor service purposes; and issuing security updates in a manner compatible with the customer's validated state — meaning that a security update must be accompanied by documentation supporting the customer's change control process. The SBOM must be maintained in machine-readable format and must cover all components including database engines, middleware, and any commercial off-the-shelf software components.

Article 13 requires a published CVD policy. For pharmaceutical automation vendors, the CVD programme must be designed to accommodate: the extended patch deployment timelines inherent in GMP-validated environments, where security patches require change control, impact assessment, and re-qualification before installation; coordination with pharmaceutical customers' quality assurance teams who must approve changes to validated systems; and the potential public health implications of manufacturing system vulnerabilities, which may warrant notification of medicines regulatory authorities (EMA, national competent authorities) in serious cases. The CVD policy should commit to providing customers with: a detailed security advisory for each resolved vulnerability; a qualification impact assessment indicating whether the update affects validated functionality; and an interim mitigation package for customers who cannot immediately apply the patch due to validation cycle timelines.

Article 14 requires CSIRT notification within 24 hours of confirmed active exploitation. For pharmaceutical automation vendors, active exploitation of manufacturing systems — manipulation of batch parameters, falsification of batch records, disruption of cleanroom environmental controls — could constitute a serious public health risk requiring concurrent notification to medicines regulatory authorities. Vendors must establish incident response procedures that activate regulatory notification and pharmaceutical customer notification simultaneously. GMP customers experiencing a confirmed cyberattack affecting their manufacturing systems will themselves have incident reporting obligations to their medicines authority — vendor notifications must be rapid and comprehensive enough to support the customer's own regulatory response. Pre-incident table-top exercises with key pharmaceutical customers are strongly advisable.

Class II pharmaceutical automation products require notified body assessment under the CRA. The CRA technical file for a pharma automation system should be structured to complement the Design Qualification (DQ) and User Requirements Specification (URS) documentation that GMP customers require. Evidence of security testing — penetration tests, code review, vulnerability scanning — supports both the CRA technical file and the customer's Installation Qualification (IQ) assessment. Vendors who provide vendors GMP qualification documentation packages as part of their product offering are well-positioned to extend this practice to CRA compliance documentation, providing customers with a security compliance pack alongside the standard IQ/OQ documentation. This approach differentiates CRA-compliant vendors in pharmaceutical procurement processes.